DG
SRPT icon

DMC Group’s Sarepta Therapeutics SRPT Stock Holding History

DMC Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,305
Closed -$211K – 137
2025
Q1 		$211K Buy
3,305
+13
+0.4% +$1.37K 0.17% 115
2024
Q4 		$400K Buy
3,292
+31
+1% +$3.8K 0.33% 92
2024
Q3 		$407K Sell
3,261
-136
-4% -$18.8K 0.33% 93
2024
Q2 		$537K Sell
3,397
-314
-8% -$40.3K 0.46% 70
2024
Q1 		$480K Sell
3,711
-82
-2% -$10K 0.42% 80
2023
Q4 		$366K Buy
3,793
+496
+15% +$47.6K 0.35% 89
2023
Q3 		$400K Buy
3,297
+93
+3% +$10.5K 0.37% 79
2023
Q2 		$367K Sell
3,204
-25
-0.8% -$3.22K 0.37% 82
2023
Q1 		$444K Buy
3,229
+34
+1% +$4.41K 0.45% 71
2022
Q4 		$399K Buy
3,195
+189
+6% +$21.9K 0.45% 70
2022
Q3 		$330K Buy
3,006
+249
+9% +$25.1K 0.4% 74
2022
Q2 		$209K Buy
2,757
+112
+4% +$8.24K 0.25% 100
2022
Q1 		$202K Buy
+2,645
New +$203K 0.23% 103

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DMC Group's SRPT Position: Q2 2025 in Review

DMC Group sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,305 shares — an estimated $211K sold.

DMC Group first reported a position in SRPT in Q1 2022 and held it in 13 quarters. The position peaked at $537K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • DMC Group reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • DMC Group sold 3,305 Sarepta Therapeutics shares in Q2 2025, an estimated $211K.
  • DMC Group first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 13 quarters.
  • DMC Group's Sarepta Therapeutics position peaked at $537K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on DMC Group's 13F filing for Q2 2025, filed 23 Jul 2025.